# Muscle Invasive Bladder Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/muscle-invasive-bladder-cancer

> No upcoming FDA catalysts in muscle Invasive Bladder Cancer; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 2, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Muscle Invasive Bladder Cancer | completed | "NCT04960709 (Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04960709)) |
| May 5, 2026 | [KEYTRUDA® (pembrolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/pembrolizumab) | PFE | muscle-invasive bladder cancer | completed | "Pfizer and Astellas Pharma Inc. announced the FDA accepted for priority review a sBLA for perioperative (before and after surgery) Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as treatment for patients with muscle-invasive bladder cancer (MIBC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| August 4, 2026 | [KEYTRUDA® (pembrolizumab) FDA approval](https://sec-api.dev/pdufa/pembrolizumab) | PFE | muscle-invasive bladder cancer | completed, approved | "Pfizer and Astellas Pharma Inc. announced FDA approval of Padcev plus pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |

## Drugs

- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/muscle-invasive-bladder-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Muscle Invasive Bladder Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/muscle-invasive-bladder-cancer

```bibtex
@misc{secapidev_indications_muscle_invasive_bladder_cancer_20261116,
  title        = {Muscle Invasive Bladder Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/muscle-invasive-bladder-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_muscle_invasive_bladder_cancer_20261116","title":"Muscle Invasive Bladder Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/muscle-invasive-bladder-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
